Key facts
- This page summarizes Peter A. Thompson's Form 4 filing for ALPINE IMMUNE SCIENCES, INC..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jan 2024, 16:36.
Peter A. Thompson - 11 Jan 2024 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 11 Jan 2024
- Net transaction value
- +$1,850,498
- SEC form
- 4
- Accepted by SEC
- 16 Jan 2024, 16:36:56 UTC
- Prior SEC filing
- 04 Jan 2024
- Next SEC filing
- 25 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter A. Thompson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter A. Thompson filed Form 4 for ALPINE IMMUNE SCIENCES, INC. on 16 Jan 2024.
Change
- Previous filing in this sequence was filed on 04 Jan 2024.
- Current net transaction value: +$1,850,498.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALPN
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $1,850,498
- Shares
- +145,251
- Change %
- +6.4%
- Price
- $12.74
- Shares after
- 2,416,181
- Date
- 11 Jan 2024
- Ownership
- See footnotes
- Footnotes
- F1, F3
ALPN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 264,315
- Date
- 11 Jan 2024
- Ownership
- See footnotes
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALPN
transaction
Derivative
Warrant (Right to Buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -145,251
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 11 Jan 2024
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 145,251
- Exercise price
- $12.74
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
Footnote F2
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
Footnote F3
Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.